Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit

doi:10.21203/rs.3.rs-95432/v1

Download PDF

Research Article

Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit

https://doi.org/10.21203/rs.3.rs-95432/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 25 Jan, 2021

Read the published version in Scientific Reports →

Version 1

posted

You are reading this latest preprint version

Purpose: Patients suffering from CVOID-19 mostly experience a benign course of the disease. Approximately 14 % of SARS-CoV2 infected patients are admitted to a hospital. Cohorts exhibiting severe lung failure in the form of acute respiratory distress syndrome (ARDS) have been well characterized. Patients without ARDS but in need of supplementary oxygen have received much less attention. This study describes the diagnosis, symptoms, treatment and outcomes of hospitalized patients with COVID-19 needing oxygen support during their stay on regular ward.

Methods: All 133 patients admitted to the RWTH Aachen university hospital with the diagnosis of COVID-19 were included in an observational registry. Clinical data sets were extracted from the hospital information system. This analysis includes all 57 patients requiring supplemental oxygen not admitted to the ICU.

Results: 57 patients needing supplemental oxygen and being treated outside the ICU were analyzed. Patients exhibited the typical set of symptoms for COVID-19. Of note, hypoxic patients mostly did not suffer from clinically relevant dyspnea despite oxygen saturations below 92 %. Patients had fever for 7 [2-11] days and needed supplemental oxygen for 8 [5-13] days resulting in an overall hospitalization time of 12 [7-20] days. In addition, patients had persisting systemic inflammation with CRP levels remaining elevated until discharge or death.

Conclusion: This description of COVID-19 patients requiring oxygen therapy should be taken into account when planning treatment capacity. Patients on oxygen need long-term inpatient care.

Pulmonology

Infectious Diseases

COVID-19

SARS-CoV2

oxygen therapy

clinical course

Since December 2019, a novel coronavirus, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been causing a rapidly spreading international outbreak; concomitantly with a primarily respiratory disease called coronavirus disease 2019 (COVID-19) [1]. Due to the different related clinical scenarios which vary from asymptomatic infection to multiorgan involvement and failure, to even death in worse cases [2, 3, 4, 5], this disease has been causing a substantial burden on healthcare systems worldwide at every level and especially on available resources. However, the epidemiological studies from different countries have shown that the majority of infected patients (> 80 %) are asymptomatic or have mild symptoms, whereas about 14 % of infected patients have a severe disease and need to be hospitalized [6, 2, 3, 5, 4, 7]. Nevertheless, among hospitalized patients, the presence and severity of respiratory failure are usually the most important clues in making the decision about admitting to the intensive care unit (ICU) in order to provide ventilatory support (non-invasive or invasive ventilation) or to treat on the regular ward. The group of ICU admitted patients has been very well characterized, and therapeutic approaches regarding ventilatory support have been well established [8, 9, 10, 11]. On the other hand, there is a group of patients which have hypoxemic respiratory failure, but still could be managed on regular ward with supplemental oxygen therapy. The characteristics of these patients have - to the best of our knowledge - not been well described so far.

We therefore describe the diagnosis, symptoms, treatment and outcomes of hospitalized patients with COVID-19 needing oxygen support during their stay on regular ward.

The protocol for this study was approved by the ethics committee of the University Hospital Aachen, Germany (EK 080/20). All investigations were performed in accordance with the ethical standards laid down in the Declaration of Helsinki in its latest revision and all patients provided written informed consent; in case patients could not provide consent, written consultant advice and next of kin permission was obtained.

Previously we compared patients with and without ARDS regarding differences and outcome [7]. The current analysis primarily focusses on patients with hypoxemic respiratory failure (defined as peripheral oxygen saturation on pulse oximetry (SpO₂) < 92 % on ambient air), which were admitted to a regular ward. Demographic data, disease history, coexisting medical conditions, presence of chronic respiratory failure, smoking history, and medication history were recorded for all patients. Symptoms at admission and a detailed history of present symptoms were also documented. Patients were assessed for eligibility on the basis of a positive reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay for SARS-CoV-2 in a respiratory tract sample tested by the local diagnostic laboratory. Viral load was also determined using RT-PCR. The threshold value Ct represents the time point, at which the exponential phase of amplification begins, which therefore is inverse proportional to virus concentration in the material investigated and reflects the relative difference on a logarithmic scale. The threshold value of the sample gene < 20, was classified as high. Values > 30 were classified as low virus load, and values between ≥ 20 and < 30 as medium virus load.

Overweight was defined as BMI > 25 kg/m² and obesity as BMI > 30 kg/m². Diabetes or prediabetes was defined by clinical history, medication and HbA_1c values ≥ 6.5 %, or ≥ 5.7 to < 6.5 %, respectively.

Vital signs including SpO₂ were measured at least two times per day and if clinically indicated and documented in the hospital electronic medical record system. The worst values in 24 hours were depicted for analysis. Febrile days were defined as the time from fever onset until the last documented value above 38.5 ℃.

Generally, supplemental oxygen was given to target SpO₂ values of > 94 % and clinical relief in patients without risk of hypercapnia, and SpO₂ values of 88-92 % with clinical relief if there was a risk of hypercapnia. The flow rates of supplemental oxygen where documented two times per day and adjusted when needed. An oxygen saturation below 92% led to an increase by 1 L / minute while a sO2 above 96% triggered a decrease in oxygen flow by 1 L / minute.

Serum, plasma, and whole blood samples were obtained routinely at the time of admission. Further blood tests were analyzed regularly as indicated, therefore patient numbers vary between different time points in the figures. Radiological and further microbiological tests were performed based on clinical decision making.

Values are displayed as median with interquartile ranges or mean ± standard error of the mean.

57 consecutive patients being hospitalized outside the ICU on an isolation ward for SARS-CoV-2 pneumonia between February and April 2020 were included into the analysis. All of them needed supplemental oxygen. At the time of this analysis, 13 of the 57 patients were deceased (23 %), while 42 (74 %) had been discharged from the hospital and 2 (4 %) were still hospitalized. 12 of the 13 non-survivors (92 %) expressed their will for a limitation of therapy during hospitalization and therefore did not wish to be resuscitated, intubated or treated on the ICU.

Patient characteristics

Baseline characteristics of all patients as well as the subgroups of non-survivors and survivors are summarized in table 1. The median age (IQR) of the overall cohort was 72 (60-81) years, and 23 % were women. Non-survivors were older compared to survivors (table 1). All patients had comorbidities, which are, as well as concomitant medication, displayed in table 2. Survivors and non-survivors exhibited a similar prevalence of arterial hypertension, pre-existing respiratory diseases or pre-existing heart diseases (table 2).

Clinical course and laboratory findings

47 (82 %) patients reported fever as an initial symptom, whereas 24 (42 %) patients had ongoing fever during hospitalization. Patients (survivors and non-survivors) had fever for 7 (2-11) days and needed supplemental oxygen for 8 (5-13) days resulting in an overall hospitalization time of 12 (7-20) days. Those being discharged had fever for 8 (2-11) days and needed supplemental oxygen for 9 (5-13) days resulting in an overall hospitalization of 13 (8-20) days (figure 1). In addition to the long period of hospitalization with fever and dependency on oxygen, inflammatory parameters were also elevated over a long time period (figure 2). In detail, 37 (65 %) patients had CRP levels above 100 mg/L and 49 (86 %) patients had CRP levels higher than 50 mg/L during hospitalization.

Vital signs as well as laboratory parameters, radiological and microbiological findings assessed at baseline are displayed in table 3 and 4. The median oxygen supply at admission was at 2 (0-4) L/min. 3 patients (5 %) had already been on long-term oxygen therapy (LTOT). The median oxygen flow during the whole period of hospitalization was 2 (0.4-2.5) L/min. The majority of patients (77%) had bilateral infiltrates. Patients who died had higher values of inflammatory parameters compared to survivors (table 3). In addition, D-dimers were elevated in all patients with higher values in those who died compared to survivors (table 3).

This study characterizes patients suffering from COVID-19 that require supplemental oxygen therapy but do not exhibit Acute Respiratory Distress Syndrome (ARDS) and can be treated outside the ICU. Several studies have focused on COVID-19 patients needing intensive care medicine [8, 9, 10, 11], but to our knowledge, patients requiring supplemental oxygen on a general ward have not been described in detail.

The patients included in this study presented with a typical set of symptoms [2]: fever, cough or fatigue were usually present. Of note, less than half (44%) of the patients exhibited dyspnea despite their hypoxemic respiratory failure, which might easily result in underestimation of the clinical severity of the disease. Peripheral oxygen saturation should thus be measured in all patients with COVID-19 at admission and routinely on regular basis during the hospital stay. All but one patient had at least one preexisting comorbidity; with hypertension, heart diseases and overweight being the most common ones.

Survivors and non-survivors in this study should be regarded as two different patient groups. While survivors were on average 16 years younger, non-survivors declined intensive care treatment. Respiratory failure led to death in the latter patients. Marked systemic inflammation reflected by IL-6 levels highlights the difference in disease severity between these groups. Also, an extra pulmonary manifestation of COVID-19 was detected in 75% of non-survivors, comparable to patients with mild ARDS. [11]

The single most outstanding finding of this study is the length of hospitalization and the need of supplemental oxygen: patients were treated for 12 days and needed oxygen therapy for 8 days on average. Importantly, comparing to patients being hospitalized because of severe influenza [12], patients with COVID-19 seem to need a significantly longer hospital stay and are longer on oxygen therapy.

The severity and the prolonged course of COVID-19 in these patients might be caused by persisting systemic inflammation reflected in fever and elevated C-reactive protein (CRP) as well as interleukin-6 (IL-6). In fact, CRP levels remained elevated until discharge or death (ref. figure 2).

In Conclusion patients with COVID-19 requiring oxygen therapy need long-term inpatient care with a median of 12 days in hospital including 8 days on supplemental oxygen, which should be taken into account when planning treatment capacity. This result could be partially explained by the prolonged inflammatory course of the disease.

World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-513.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. February 7 (Epub ahead of print).
Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020. February 7 (Epub ahead of print).
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020
Dreher et al. Charakteristik von 50 hospitalisierten COVID-19-Patienten mit und ohne ARDS. Dtsch Arztebl Int 2020; 117: 271-8; DOI: 10.3238/arztebl.2020.0271
Richardson S et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 Apr 22. doi: 10.1001/jama.2020.6775.
Myers et al. Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California.
Phua J, Weng L, Ling L et al (2020) Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med.
Gattinoni L, Coppola S, Cressoni M et al (2020) Covid-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med.
Lee, N., Choi, K., Chan, P., Hui, D., Lui, G., Wong, B., Wong, R., Sin, W., Hui, W., Ngai, K., Cockram, C., Lai, R. and Sung, J., 2010. Outcomes of adults hospitalised with severe influenza. Thorax, 65(6), pp.510-515.

Table 1: Baseline characteristics
	Total (N=57)	Non-Survivors (N=13)	Survivors (N=42)
Charakteristics
Age - Median (IQR), years	72 (60-81)	81 (76-86)	65 (56-78)
Female Sex - N (%)	13 (23)	2 (15)	10 (24)
Initial symptoms - N (%)
Fever	39 (68)	9 (69)	29 (69)
Cough	34 (60)	10 (77)	23 (55)
Dyspnea	25 (44)	4 (31)	21 (50)
Fatigue	21 (37)	3 (23)	18 (43)
Gastrointestinal Symptoms	17 (30)	1 (8)	16 (38)
Diarrhea	13 (23)	0 (0)	13 (31)
Emesis	3 (5)	1 (8)	2 (5)
Nausea	9 (16)	1 (8)	8 (19)
Tiredness	16 (28)	1 (8)	15 (36)
Myalgia	12 (21)	1 (8)	11 (26)
Loss of Taste	10 (18)	1 (8)	9 (21)
Loss of Smell	9 (16)	1 (8)	8 (19)
Headache	7 (12)	0 (0)	7 (17)
Sore throat	4 (7)	0 (0)	4 (7)
Angina pectoris	4 (7)	0 (0)	4 (10)
Pharyngalgia	3 (5)	1 (8)	2 (5)
Rhinorrhoea	2 (4)	0 (0)	2 (5)
Symptom onset to - Median (IQR), days
Hospitalization	4 (0-7)	0 (0-2)	6 (1-7)
Inpatient treatment - N (%)
Antibotic therapy	22 (39)	9 (69)	11 (26)
Periods - Median (IQR), days
Fever days	7 (2-11)	8 (4-11)	8 (2-11)
Hospitalization	12 (7-20)	9 (6-15)	13 (8-20)
Oxygen supplementation	8 (5-13)	7 (4-10)	9 (5-13)
Outcome - N (%)
Survivor	42 (74)	-	-
Non-Survivor	13 (23)	-	-
Ongoing hospitalization	2 (4)	-	-

Data in N (%) or Median (IQR). IQR=Interquartile range.

Table 2: Comorbidities and Premedication
	N (%)
	Total (N=57)	Non-Survivors (N=13)	Survivors (N=42)
Comorbidities
Total	56 (98)	13 (100)	41 (98)
Arterial hypertension	33 (58)	10 (77)	21 (50)
Pre-existing heart diseases	22 (39)	5 (38)	15 (36)
Cardiovascular disease	15 (26)	4 (31)	11 (26)
Atrial fibrillation	11 (19)	4 (31)	6 (14)
Heart failure	12 (21)	2 (15)	8 (19)
Pre-existing respiratory disease	20 (35)	5 (38)	15 (36)
COPD	10 (18)	1 (8)	9 (21)
Obstructive sleep apnea syndrome	5 (9)	2 (15)	3 (7)
Asthma bronchiale	5 (9)	2 (15)	3 (7)
Other pulmonary diseases	8 (14)	3 (23)	5 (12)
Smoking	19 (33)	2 (15)	17 (40)
Former smoking	8 (14)	2 (15)	6 (14)
Continued smoking	7 (12)	0 (0)	7 (17)
Overweight (BMI ≥ 25 kg/m², < 30 kg/m²)	17 (30)	2 (15)	14 (33)
Obesity (BMI ≥ 30 kg/m²)	12 (21)	1 (8)	11 (26)
Diabetes mellitus	17 (30)	5 (38)	10 (24)
Prediabetes	10 (18)	3 (23)	7 (17)
Chronic kidney disease	10 (18)	3 (23)	6 (14)
Malignancy	10 (18)	3 (23)	6 (14)
Cerebrovascular disease	6 (11)	1 (8)	4 (10)
Chronic hepatits	4 (7)	1 (8)	3 (7)
Peripheral aterial occlusive disease	3 (5)	1 (8)	2 (5)
Chronic liver failure	3 (5)	1 (8)	2 (5)
Premedications
ACE-Inhibitors	20 (35)	6 (46)	14 (33)
Angiotensin-receptor blockers	14 (25)	2 (15)	11 (26)
Beta blocker	20 (35)	7 (54)	11 (26)
Calcium antagonists	15 (26)	2 (15)	12 (29)
Diuretics	29 (51)	10 (77)	17 (40)
Antidiabetics	13 (23)	4 (31)	8 (19)
Lipid-lowering agents	16 (28)	6 (46)	10 (24)
Antiplatelets	19 (33)	5 (38)	14 (33)
Anticoagulants	11 (19)	4 (31)	6 (14)
Inhalatives	16 (28)	2 (15)	13 (31)
Inhalative Glucocorticoids	5 (9)	1 (8)	4 (10)
Systemic Glucocorticoids	5 (9)	1 (8)	4 (10)
Immunosuppressants	4 (7)	0 (0)	3 (7)
NSAR	11 (19)	0 (0)	11 (26)
Antibiotics	11 (19)	5 (38)	5 (12)
Virostatics	1 (2)	0 (0)	1 (2)

Data in N (%). COPD=chronic obstructive pulmonary disease. BMI=body mass index. ACE=angiotensin-converting enzyme. NSAR=non-steroidal anti rheumatics.

Table 3: Vital and laboratory parameters
		Median (IQR)
	Reference values	Total (N=57)	Non-Survivors (N=13)	Survivors (N=42)
Vital parameters
Height [cm]		172 (166-178)	173 (164-180)	173 (167-178)
Weight [kg]		75 (66-80)	75 (66-80)	84 (72-91)
BMI [kg/m²]		24.8 (23.5-27.2)	24.8 (23.5-27.2)	27.7 (24.2-30.3)
Respiratory rate [bpm]		22 (18-26)	24 (17.5-28.3)	21 (18-25.8)
Oxygen saturation [%]		94 (91-96)	94 (92-95)	95 (90.3-97)
Oxygen flow [l/min]		2 (0-4)	3 (2-7)	2 (0-2)
Temperature [°C]		37.9 (36.9-38.6)	37.8 (37-38.5)	37.9 (36.9-38.6)
RRsys [mmHg]		125 (101-140)	127 (110-140)	126 (103-140)
RRdia [mmHg]		71 (60-80)	67 (57-78)	74 (60-80)
Heart rate [bpm]		88 (80-100)	88 (71-103)	90 (80-100)
Admission Labs
Leukocytes [1/nl]	4.0-10.0	6.9 (5.1-9.5)	8.7 (5.9-9.3)	6.7 (4.5-9.4)
Hb [g/dl]	m: 14.0-18.0	13.4 (10.3-14.5)	10.4 (10.1-13.5)	13.9 (12.1-14.6)
	w: 12.0-16.0
Thrombocytes [1/nl]	150-400	180 (144-232)	148 (134-315)	187.5 (148.5-225.8)
Lymphocytes [%]	22.0-53.0	10.4 (7-15.2)	7 (4.4-12.3)	11.6 (9.1-20.5)
INR		1.2 (1.1-1.3)	1.2 (1.1-1.4)	1.2 (1.1-1.3)
aPTT [sec]	25.1 – 36.5	27.8 (26-30.7)	28.6 (26.1-30.9)	27.8 (26.2-30.4)
D-Dimere [ng/ml]	< 500	855 (622-1086)	16401 (11158-21644)	738.5 (595.8-881.3)
HbA1c [%]	< 5.7	6.1 (5.5-6.7)	6.1 (5.8-6.8)	5.8 (5.4-6.6)
Sodium [mmol/l]	136-145	139 (136-141.3)	141 (138-143)	139 (136-141)
Potassium [mmol/l]	3.6-5.5	4.2 (3.8-4.6)	4.2 (3.6-4.7)	4.2 (3.8-4.6)
Albumin [g/dl]	3.5-5.2	3.2 (2.7-3.8)	3.8 (3.6-3.9)	2.9 (2.7-3.8)
Bilirubin (total)	< 1.2	0.6 (0.5-0.9)	0.9 (0.4-1.1)	0.6 (0.5-0.7)
AST [U/l]	< 35	41.5 (30-55.3)	42 (27-72)	41 (33-55)
ALT [U/l]	< 35	27 (20-37)	25.5 (20.8-29.5)	30 (20-41)
Gamma-GT	< 40	31 (23-68)	57 (32.5-110.8)	31 (23-65)
AP	35-105	65 (47-82.5)	98 (84-158.5)	61.5 (44.3-80.3)
LDH [U/l]	m: 135-225	339 (277-442)	416 (332-452)	339.5 (273.3-436)
	w: 135-214
CK [U/l]	m: < 174	132 (82.8-285.5)	96 (62-400)	150.5 (98-285.5)
	w: < 140
CK-MB-Activity [U/l]	< 26 U/l	16 (11-18)	18 (14-18.5)	16 (12-18)
hsTroponin T [pg/ml]	< 14.0	83.5 (27.3-131)	81 (68.5-93.5)	93 (28-179)
NTproBNP [pg/ml]	< 220	726 (198.2-1393)	1730.5 (663.7-3028.3)	323.9 (71.5-1237)
Urea [mg/dl]	16.6-48.5	40 (29.5-65.5)	48.5 (41-69.3)	38 (27-58)
Creatinine [mg/dl]	0.5-1.2	1 (0.9-1.4)	1 (0.9-2)	1 (0.9-1.2)
CRP [mg/l]	< 5	68.1 (29.9-119.8)	96.6 (31.3-135.4)	67 (28.2-109.9)
PCT [ng/ml]	< 0.5	0.1 (0.1-0.2)	0.1 (0.1-0.3)	0.1 (0.1-0.2)
IL-6 [pg/ml]	< 7.0	64.2 (40.1-124.3)	697.8 (374.2-1021.4)	67.5 (42.1-123.6)
Ferritin [ng/ml]	15.0 - 150.0	832.8 (455.6-1136.3)	221.7 (221.7-221.7)	1140.5 (1136.3-1144.8)

Data in Median (IQR). IQR=interquartile range. BMI=body mass index. RR=arterial blood pressure after Scipione Riva Rocci. Hb=hemoglobin. INR=international normalized ratio. aPTT=activated partial thromboplastin time. AST=aspartate aminotransferase. ALT=alanine aminotransferase. Gamma-GT=gamma-glutamyltranspeptidase. AP=alkaline phosphatase. LDH=lactate dehydrogenase. CK=creatine kinase. hs=high sensitive. NTproBNP=N-terminale pro brain natriuretic peptide. CRP=C-reactive protein. PCT=procalcitonin. IL-6=interleukin-6.

Table 4: Radiological and microbiological findings
	N/N total (%)
	Total (N=57)	Non-Survivors (N=13)	Survivors (N=42)
Chest radiography
no infiltrates	7/53 (13)	3/13 (23)	3/38 (8)
unilateral infiltrates	5/53 (9)	2/13 (15)	3/38 (8)
bilateral infiltrates	41/53 (77)	8/13 (62)	32/38 (84)
Viral load
High	11/52 (21)	4/12 (33)	7/38 (18)
Medium	29/52 (56)	7/12 (58)	21/38 (55)
Low	12/52 (23)	1/12 (8)	10/38 (26)
Ct S-Gen - Median (IQR)	24,8 (19,2-29,6)	22,8 (17,9-28,2)	24,1 (19,9-28,8)
Viral detection
Pulmonary manifestation	52/56 (93)	12/13 (92)	38/41 (93)
positive out of hospital	7 (12)	1 (8)	6 (14)
Extrapulmonary manifestation	11/34 (32)	3/4 (75)	8/28 (29)
Serum	6/28 (21)	2/4 (50)	4/22 (18)
Stool	5/15 (33)	1/3 (33)	4/12 (33)
Urine	4/24 (17)	2/4 (50)	2/18 (11)
Bacterial detection
Blood culture	3/44 (7)	1/12 (8)	2/30 (7)
Urine culture	16/38 (42)	3/9 (33)	11/27 (41)

Download PDF

Journal Publication

published 25 Jan, 2021

Read the published version in Scientific Reports →

Version 1

posted

You are reading this latest preprint version

Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Methods

Results

Discussion

References

Tables

Status:

Journal Publication

Version 1